In addition, CD79A represents an effective inhibitor target for human B cell activation, rendering it a promising therapeutic option for autoimmune diseases such as systemic lupus erythematosus and collagen-induced arthritis (38, 39). The gene discussed is CD79A; the disease is systemic lupus erythematosus.